CagriSema
Also known as: cagrisema
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Who's worth your money for CagriSema
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 4 scored sellers
$143 · 20mg · 99.8% purity
Best value
Lowest $/mg among scored sellers
$99.99 · 35mg
Average price
$9.06/mg
Sellers
7
45-day trend
+4%
7 of 7 sellers have a current price· 2 stale hidden· 1 unverified hidden
Top Merit pick
🇺🇸 Profound Aminos95via Disclosed Labs · just now
$7.15/mg -21.1% vs avg$143
20mg
- 🇺🇸 Polaris Peptides90
via Disclosed Labs · just now
$7.45/mg -17.8% vs avg$149
20mg
no purity - optimasupply.is86
via Disclosed Labs · just now
$13.00/mg +43.5% vs avg$130
10mg
no purity - Modern Research Peptides82
via Disclosed Labs · just now
$2.86/mg -68.5% vs avg$99.99
35mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch CagriSema
Get one email when the market actually moves — no newsletter, no noise.
About CagriSema
CAS
—
Molecular formula
—
Typical dose range
2.4 mg/week cagrilintide + 2.4 mg/week semaglutide, subcutaneous once-weekly; dose-escalation starting at 0.16 mg/week cagrilintide escalated over 16 weeks
Half-life
Cagrilintide ~184 hours (~7.7 days); semaglutide ~158 hours (~6.6 days)
COAs for CagriSema
7 third-party tests across 5 vendors. Each card links to the full report.
For
CagriSema
by Simple Peptide· batch 02-21101-02905-P
For
CagriSema
by Simple Peptide· batch CGSM09032025-J
For
CagriSema
by Profound Aminos· batch 2025-04-31
For
CagriSema
by Hydro Research Peptides· batch 2024-08-05
For
CagriSema
by Profound Aminos· batch cmojb7ss001e3kirxyi4q8sbq
Purity not on file
For
Cagrisema
by Peptide Crafters· batch PC-J2-CS10
Purity not on file
For
Cariintide/Semaglutide
by Certified Peptides· batch 251227CS53
20 citations indexed for CagriSema
Study · 2026
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
Importance Cagrilintide-semaglutide (CagriSema) is a fixed-dose combination of the amylin receptor agonist cagrilintide and the glucagon-like peptide-1 receptor agonist semaglutide administered subcutaneously once weekly.
Study · 2026
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials
Background Overweight status, obesity, and diabetes represent significant socioeconomic burdens that require long-term management.
review · 2026
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Introduction Type 2 diabetes mellitus (T2DM) and obesity represent two major global health challenges. Amylin-based agonists offer a promising perspective. Three frontrunner agents of this class are increasingly being investigated: zenagamtide, eloralintide and cagrilintide-semaglutide (CagriSema).
review · 2026
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
Study · 2026
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Background Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
rct · 2026
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity.